Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AXL1717 + Brigatinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AXL1717 | Picropodophyllin|PPP|Picropodophyllotoxin | IGF-1R Inhibitor 17 | AXL1717 (picropodophyllin) inhibits IGF-1R, potentially leading to decreased tumor growth (PMID: 21875414, PMID: 31340850). | |
Brigatinib | Alunbrig | AP26113 | ALK Inhibitor 32 EGFR Inhibitor (Pan) 62 FLT3 Inhibitor 69 IGF-1R Inhibitor 17 ROS1 Inhibitor 20 | Alunbrig (brigatinib) is a multi-kinase inhibitor with selected activity against ALK, ROS1 fusions, FLT3, IGF1R and mutant EGFR, potentially resulting in decreased tumor growth (PMID: 27780853). Alunbrig (brigatinib) is FDA approved for use in patients with ALK-positive metastatic non-small cell lung cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|